Exome Asset Management LLC reported 52 positions worth $162.10M for the quarter ended Jun 30, 2026, down 1.4% on the prior quarter. It opened 15 new positions, added to 1, trimmed 32 and exited 6. Its largest holding is Guardant Health, Inc. at 6.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TGTX Tg Therapeutics, Inc. | +164.9K | – | $9.06M | 5.59% |
| ABVX Abivax S.A. | +46.9K | – | $6.25M | 3.85% |
| QURE uniQure N.V. | +81.1K | – | $3.73M | 2.3% |
| AZN Astrazeneca Plc | +12.0K | – | $2.25M | 1.39% |
| VKTX Viking Therapeutics, Inc. | +47.9K | – | $1.87M | 1.15% |
| OCUL Ocular Therapeutix, Inc | +181.6K | – | $1.78M | 1.1% |
| EQ Equillium, Inc. | +553.0K | – | $1.77M | 1.09% |
| ASND Ascendis Pharma A/S | +6,573 | – | $1.75M | 1.08% |
| NKTR Nektar Therapeutics | +22.4K | – | $1.56M | 0.965% |
| CLPT ClearPoint Neuro, Inc. | +83.6K | – | $1.49M | 0.92% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | -18.3K | -40.2% | $6.11M | 5.62% |
| ELVN Enliven Therapeutics, Inc. | -119.9K | -54.5% | $6.08M | 3.14% |
| RLAY Relay Therapeutics, Inc. | -230.8K | -82.9% | $4.32M | 0.549% |
| ELV Elevance Health, Inc. | -14.7K | -100.0% | $4.30M | Exited |
| CYTK Cytokinetics Inc | -43.7K | -42.1% | $3.72M | 3.16% |
| BBIO BridgeBio Pharma, Inc. | -49.1K | -72.8% | $3.66M | 0.844% |
| COGT Cogent Biosciences, Inc. | -68.0K | -24.4% | $2.63M | 5.03% |
| AVTX Avalo Therapeutics, Inc. | -159.3K | -100.0% | $2.38M | Exited |
| GH Guardant Health, Inc. | -15.2K | -18.4% | $2.29M | 6.25% |
| ALMS Alumis Inc. | -74.8K | -26.8% | $2.10M | 3.55% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TGTX Tg Therapeutics, Inc. | +164.9K | $9.06M | 5.59% |
| ABVX Abivax S.A. | +46.9K | $6.25M | 3.85% |
| QURE uniQure N.V. | +81.1K | $3.73M | 2.3% |
| AZN Astrazeneca Plc | +12.0K | $2.25M | 1.39% |
| VKTX Viking Therapeutics, Inc. | +47.9K | $1.87M | 1.15% |
| OCUL Ocular Therapeutix, Inc | +181.6K | $1.78M | 1.1% |
| EQ Equillium, Inc. | +553.0K | $1.77M | 1.09% |
| ASND Ascendis Pharma A/S | +6,573 | $1.75M | 1.08% |
| NKTR Nektar Therapeutics | +22.4K | $1.56M | 0.965% |
| CLPT ClearPoint Neuro, Inc. | +83.6K | $1.49M | 0.92% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ELV Elevance Health, Inc. | -14.7K | $4.30M | 2.61% |
| AVTX Avalo Therapeutics, Inc. | -159.3K | $2.38M | 1.45% |
| FDMT 4D Molecular Therapeutics, Inc. | -130.6K | $1.22M | 0.739% |
| NXTC NextCure, Inc. | -115.5K | $1.22M | 0.739% |
| PALI Palisade Bio, Inc. | -600.0K | $1.05M | 0.639% |
| LPCN Lipocine Inc. | -60.9K | $486.28K | 0.296% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GH Guardant Health, Inc. | Healthcare | 67.5K | $10.13M | 6.25% | -15.2K | -18.4% | Reduced | 0.05% |
| 2 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 27.2K | $9.11M | 5.62% | -18.3K | -40.2% | Reduced | 0.09% |
| 3 | TGTX Tg Therapeutics, Inc. | Healthcare | 164.9K | $9.06M | 5.59% | +164.9K | – | New | 0.11% |
| 4 | COGT Cogent Biosciences, Inc. | Healthcare | 210.5K | $8.15M | 5.03% | -68.0K | -24.4% | Reduced | 0.12% |
| 5 | IONS Ionis Pharmaceuticals Inc | Healthcare | 88.2K | $6.99M | 4.31% | -21.9K | -19.9% | Reduced | 0.05% |
| 6 | LLY ELI LILLY & Co | Healthcare | 5,492 | $6.59M | 4.06% | -1,520 | -21.7% | Reduced | 0% |
| 7 | ABVX Abivax S.A. | Healthcare | 46.9K | $6.25M | 3.85% | +46.9K | – | New | 0.07% |
| 8 | ALMS Alumis Inc. | Healthcare | 204.4K | $5.75M | 3.55% | -74.8K | -26.8% | Reduced | 0.16% |
| 9 | CYTK Cytokinetics Inc | Healthcare | 60.1K | $5.12M | 3.16% | -43.7K | -42.1% | Reduced | 0.04% |
| 10 | ELVN Enliven Therapeutics, Inc. | Healthcare | 100.2K | $5.09M | 3.14% | -119.9K | -54.5% | Reduced | 0.14% |
| 11 | VERA Vera Therapeutics, Inc. | Healthcare | 97.3K | $4.17M | 2.57% | -17.7K | -15.4% | Reduced | 0.14% |
| 12 | UNH Unitedhealth Group Inc | Healthcare | 9,612 | $4.00M | 2.46% | -3,250 | -25.3% | Reduced | 0% |
| 13 | TXG 10x Genomics, Inc. | Healthcare | 102.6K | $3.93M | 2.43% | -51.6K | -33.4% | Reduced | 0.08% |
| 14 | NTRA Natera, Inc. | Healthcare | 13.8K | $3.75M | 2.31% | -4,850 | -26.0% | Reduced | 0.01% |
| 15 | QURE uniQure N.V. | Healthcare | 81.1K | $3.73M | 2.3% | +81.1K | – | New | 0.12% |
Tip. Select a row to see that position’s full history at Exome Asset Management.
As of its Q2 2026 13F filing, Exome Asset Management LLC’s five largest positions were Guardant Health, Inc. (GH) at 6.2%, Praxis Precision Medicines, Inc. (PRAX) at 5.6%, Tg Therapeutics, Inc. (TGTX) at 5.6%, Cogent Biosciences, Inc. (COGT) at 5.0%, Ionis Pharmaceuticals Inc (IONS) at 4.3% of the reported portfolio.
Exome Asset Management LLC reported a 13F portfolio worth $162.10M across 52 positions for Q2 2026. That is down 1.4% from the previous quarter.
Its largest purchases by value were Tg Therapeutics, Inc. ($9.06M), Abivax S.A. ($6.25M), uniQure N.V. ($3.73M). It opened 15 new positions.
Its largest sales by value were Praxis Precision Medicines, Inc. ($6.11M), Enliven Therapeutics, Inc. ($6.08M), Relay Therapeutics, Inc. ($4.32M). It exited 6 positions entirely.
From the Form 13F-HR reports Exome Asset Management LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.